Sarah McMullen
Family Medicine · Batesville, INNPI 1144623315
Payments from drug & device makers
Across 92 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$219
- Novo Nordisk$197
- GSK$148
- AbbVie$105
- Ultragenyx Pharmaceutical Inc.$101
- Abbott$98
- plus $540 from 21 others
What the payments were for
- Food & beverage$1,404100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $219 |
| Novo Nordisk | 13 | $197 |
| GSK | 10 | $148 |
| AbbVie | 6 | $105 |
| Ultragenyx Pharmaceutical Inc. | 6 | $101 |
| Abbott | 6 | $98 |
| Amgen | 6 | $78 |
| Exact Sciences | 3 | $60 |
| AstraZeneca | 4 | $58 |
| Johnson & Johnson | 3 | $38 |
| Novartis | 2 | $35 |
| Merck | 2 | $26 |
| Bayer | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Abiomed | 1 | $20 |
| Halozyme Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Biogen | 1 | $11 |
How this compares
$1,408 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $94,729 |
| EliquisApixaban | 64 | $66,907 |
| MounjaroTirzepatide | 44 | $46,638 |
| XareltoRivaroxaban | 31 | $39,747 |
| JardianceEmpagliflozin | 32 | $38,541 |
| FarxigaDapagliflozin Propanediol | 31 | $28,190 |
| JanuviaSitagliptin Phosphate | 23 | $26,031 |
| TrulicityDulaglutide | 16 | $21,226 |
| RybelsusSemaglutide | 13 | $20,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,399 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $11,180 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $9,053 |
| Memantine Hcl ErMemantine Hcl | 13 | $4,218 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $3,948 |
| Duloxetine Hcl | 121 | $3,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $197 | $114,77097 claims |
| PfizerEliquis | $219 | $66,90764 claims |
| Johnson & JohnsonXarelto | $38 | $39,74731 claims |
| AstraZenecaFarxiga | $58 | $28,19031 claims |
| MerckJanuvia | $26 | $26,03123 claims |
| GSKTrelegy Ellipta | $148 | $18,39923 claims |
| AbbVieSynthroid | $105 | $1,59422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Batesville
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.